drugset / Trial / NCT00904176

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

NCT00904176

Phase 1 Completed 30 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is determine that Dapagliflozin has no effect on the pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin when dapagliflozin is coadministered with warfarin. Also, that Dapagliflozin has no effect on the PK of digoxin when dapagliflozin is coadministered with digoxin.

Timeline

Start
2009-06
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 10 mg Oral
Comparator Digoxin Other / unclassified 0.25 unknown Oral
Comparator Warfarin Small molecule 25 mg Oral